Jamjoom Pharma profit up 22% to SAR 356.5M in 2024; Q4 at SAR 51.6M

25/02/2025 Argaam Exclusive

Content Summary:

Loading data...

Comments Analysis:

Positive: 0%
Neutral: 0%
Negative: 0%
Comments Summary:Loading data...
Please note that this news summary has been generated using artificial intelligence. It is recommended to review the original sources for complete details and to verify the accuracy of the information.
0

Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) posted a net profit of SAR 356.5 million in 2024, rising from SAR 292.4 million a year earlier.



Financials (M)

Item 2023 2024 Change‬
Revenues 1,100.82 1,318.48 19.8 %
Gross Income 703.84 820.50 16.6 %
Operating Income 313.38 380.70 21.5 %
Net Income 292.40 356.52 21.9 %
Average Shares 70.00 70.00 -
Earnings Per Share before unusual items (Riyals) 4.18 5.09 21.9 %
EPS (Riyals) 4.18 5.09 21.9 %

The profit increase was buoyed by 19.8% revenue growth year-on-year (YoY), driven by successful strategic initiatives to expand sales in key markets and therapeutic areas. This growth was supported by the launch of new products and enhanced manufacturing capabilities, thanks to the modern facilities operating in Egypt and Saudi Arabia.

 

Additionally, the overall expansion in the pharmaceutical market contributed to strong revenue.

 

Profits from the joint venture in Algeria contributed to the growth in profits, compensating for the negative impact of foreign currencies due to the depreciation of the Egyptian pound.



Current Quarter Comparison (M)

Compared With The
Item Q4 2023 Q4 2024 Change‬
Revenues 208.96 259.70 24.3 %
Gross Income 118.91 158.51 33.3 %
Operating Income 42.24 54.18 28.3 %
Net Income 44.48 51.61 16.0 %
Average Shares 70.00 70.00 -
Earnings Per Share before unusual items (Riyals) 0.64 0.74 16.0 %
EPS (Riyals) 0.64 0.74 16.0 %

The fourth-quarter earnings jumped 16% to SAR 51.6 million, compared to SAR 44.48 million in the year-ago period.

 

On a quarterly basis, the company posted a 45.7% decline in Q4 profit from SAR 94.99 million.

 

Shareholders’ equity, no minority interest, increased to SAR 1.49 billion as of Dec. 31, 2024, compared to SAR 1.40 billion a year earlier.

 

Attached Documents

 

View More Financial Results

 

View other reports

Share Price

Jamjoom Pharmaceuticals Factory Co.
150.60
(2.80) (1.83 %)

Jamjoom Pharmaceuticals Factory Co. (JAMJOOM PHARMA)

More


Financial Ratios
Current
Market Cap (M Riyal) 10,738.00
Enterprise Value (EV) (M) 10,475.69
Shares Outstanding ((M)) 70.00
EPS ( Riyal) (TTM) 5.09
Book Value (BV) ( Riyal) 21.29
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 30.12
P/E (TTM) 30.12
Price/book 7.20
Return on Average Assets (%) (TTM) 20.8
Return on Average Equity (%) (TTM) 24.6
more

Kindly, you can view the full report by subscribing to the Advanced Package

The report contains the details of the financial statements, The most important financial indicators, Historical information, Charts, and Forecasts of experts.

Contact Us (+966)-92000-7759

Comments 0

Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Popular Links

Quick Links

Join Us

Argaam.com Copyright © 2025, Argaam Investment, All Rights Reserved
Call Request

Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.

Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website